A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel.

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Abstract Text:

Parvesh Kumar,

Survival and biochemical outcome of patients with localized, high-risk prostate cancer treated with definitive three-dimensional conformal radiation therapy (3-D CRT) with or without hormonal therapy are poor. Other therapeutic strategies are needed to improve outcome in these poor-prognostic-group patients. One such strategy involves the use of chemotherapeutic agents to radiosensitize the effects of local 3-D CRT. Very few investigators have tested this novel concept of chemotherapeutic radiosensitization. Two studies evaluated the combination of estramustine phosphate and vinblastine (EV) with radiation therapy (RT). In both studies, the combination of EV and RT resulted in moderate to severe acute and late toxicity. A recently completed, phase I trial evaluated the maximally tolerated dose (MTD) of weekly docetaxel that could be concurrently delivered with 3-D CRT (70.2 Gy) in men with high-risk prostate cancer. The MTD of concurrent weekly docetaxel with 3-D CRT was determined to be 20 mg/m(2), and this combination was shown to be safe and well tolerated. This was the first trial to evaluate taxane radiosensitization in prostate cancer. Other phase I/II studies are needed to further assess chemotherapeutic radiosensitization in localized, high-risk prostate cancer.

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Publishing Authors By Initials

P Kumar,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Reviews in urology

VOLUME: 5 Suppl 3

Page Numbers: S71-7

Journal Abbreviation:

ISSN: 1523-6161

DAY: 20

MONTH: 09

YEAR: 2003

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100889067

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Rev Urol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel Related Publications

• A modified Plasmodium falciparum growth inhibition assay (GIA) to assess activity of plasma from malaria endemic areas.
• A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel.
• An inherent role of microtubule network in the action of nuclear receptor.
• Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude.
• Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer.
• Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action.
• Cognitive function in adults with type 2 diabetes and major depression.
• Diagnosis and management of extensive vertex birth molding.
• Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.
• Effect of individual and multiple antioxidant vitamins on growth and morphology of human nontumorigenic and tumorigenic parotid acinar cells in culture.
• Functional analysis of alternative isoforms of the transcription factor PAX3 in melanocytes in vitro.
• HPA axis activity and neuropathogenesis in HIV-1 clade C infection.
• How substance use differs among American secondary schools.
• Influence of Agrobacterium rhizogenes Strains on Biomass and Alkaloid Productivity in Hairy Root Lines of Hyoscyamus muticus and H. albus *.
• Letter to the editor: The suckling-micturition reflex in cows.
• Metal-binding properties of human centrin-2 determined by micro-electrospray ionization mass spectrometry and UV spectroscopy.
• Metastasis tumor antigens, an emerging family of multifaceted master coregulators.
• Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway.
• Modification of the expression of adenosine 3',5'-cyclic monophosphate-induced differentiated functions in neuroblastoma cells by beta-carotene and D-alpha-tocopheryl succinate.
• P21-activated kinases in human cancer.
• Pituitary abscess: Report of four cases and review of literature.
• Potential medicinal plants for CNS disorders: an overview.
• Protein disulfide isomerase assisted protein folding in malaria parasites.
• Quality of life in HIV subtype C infection among asymptomatic subjects and its association with CD4 counts and viral loads--a study from South India.
• Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.
• Sexual differentiation and development in the malaria parasite.
• Standard wound coverage techniques for extremity war injury.
• Systemic, cellular and molecular analysis of chemoreflex-mediated sympathoexcitation by chronic intermittent hypoxia.
• Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV.
• p21-activated kinase signaling in breast cancer.